APH logo

Alliance Pharma plc Stock Price

AIM:APH Community·UK£350.3m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 12 Fair Values set on narratives written by author

APH Share Price Performance

UK£0.65
0.04 (5.72%)
UK£0.65
0.04 (5.72%)
Price UK£0.65

APH Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Undervalued with reasonable growth potential.

0 Risks
3 Rewards

Alliance Pharma plc Key Details

UK£178.8m

Revenue

UK£69.6m

Cost of Revenue

UK£109.3m

Gross Profit

UK£120.0m

Other Expenses

-UK£10.7m

Earnings

Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
-0.02
61.11%
-6.00%
44.5%
View Full Analysis

About APH

Founded
1996
Employees
290
CEO
Nicholas Sedgwick
WebsiteView website
www.alliancepharmaceuticals.com

Alliance Pharma plc, a holding company, acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. It provides its products under the Aloclair, Anbesol, Asthon & Parsons, Forceval, Hydromol, Kelo-Cote, MacuShield, Vamousse, Nizoral, and Amberen brand names. The company was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.

Recent APH News & Updates

Recent updates

No updates